CSLLY - CSL to acquire Vifor Pharma for $11.7B

CSL (OTCPK:CSLLY -4.2%) to launch an all-cash public tender offer to acquire all publicly held Vifor Pharma shares for US$179.25 per Vifor Pharma share, for an aggregate equity value for Vifor Pharma of US$11.7 / A$16.4B. Patinex AG, Vifor Pharma's largest shareholder holding 23% of Vifor Pharma's share capital, has agreed to tender its shares. US$12.3B / A$17.2B all-cash acquisition consideration to be funded through a combination of A$6.3B (US$4.5B) fully underwritten placement, $6.0B / A$8.4B new debt and existing cash / undrawn facilities. "Vifor Pharma enhances CSL's patient focus and ability to protect the health of those facing a range of rare and serious medical conditions. It brings an outstanding team and a leading portfolio of products across Nephrology, Dialysis and Iron Deficiency therapies and a proven partnering and business development and licensing strategy. Vifor Pharma will also expand our presence in the rapidly growing nephrology market, while giving us

For further details see:

CSL to acquire Vifor Pharma for $11.7B